Clinical Trial: Myeloma Checkpoint Inhibitor With or Without Lenalidomide - HealthTree for Multiple Myeloma
[logo] HealthTree Foundation
search person

Clinical Trial: Myeloma Checkpoint Inhibitor With or Without Lenalidomide

Posted: Aug 19, 2016
Clinical Trial: Myeloma Checkpoint Inhibitor With or Without Lenalidomide image

Checkpoint inhibitors are now entering myeloma clinical trials and are immunotherapy drugs that can be added to existing myeloma treatments. Multiple myeloma puts the brakes on the immune system and these type of immunotherapies remove that brake so the immune system can regain its ability to fight myeloma. Lenalidomide is known to enhance the immune system, so in this study, Genentech is determining whether MPDL3280A (Anti-Programmed Death Ligand 1 [aPD-L1] Antibody)  is most effective with or without lenalidomide. This is a phase I study that is open at 8 myeloma research centers around the United States. The trial objective is to enroll 46 patients.

To find this study on SparkCures, click here:

Anti PDL-1 Antibody Clinical Trial

Checkpoint inhibitors are now entering myeloma clinical trials and are immunotherapy drugs that can be added to existing myeloma treatments. Multiple myeloma puts the brakes on the immune system and these type of immunotherapies remove that brake so the immune system can regain its ability to fight myeloma. Lenalidomide is known to enhance the immune system, so in this study, Genentech is determining whether MPDL3280A (Anti-Programmed Death Ligand 1 [aPD-L1] Antibody)  is most effective with or without lenalidomide. This is a phase I study that is open at 8 myeloma research centers around the United States. The trial objective is to enroll 46 patients.

To find this study on SparkCures, click here:

Anti PDL-1 Antibody Clinical Trial

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can contribute to cures by joining HealthTree Cure Hub and joining clinical research. Founder and CEO of HealthTree Foundation. 

newsletter icon

Your Source for Expert Insights & Support in Multiple Myeloma.

By subscribing to the Healthtree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.

Follow Us

facebook instagram linkedin tiktok youtube